[Ibrutinib - new tool in hematologist hand, new challenges for internist].
Chronic lymphocytic leukemia is the most common cancer of the lymphatic tissue in adults. The peak incidence falls on the 65-70 year old. Therefore, the majority of patients with chronic lymphocytic leukemia (CLL) has at least one coexisting disease. Successful oncological and supportive treatment, that is common in recent years, significantly prolongs the survival. This paper presents ibrutinib - a new drug used to treat CLL. The aim of this paper is, to show an example of this drug, meaning and benefits of modern methods of pharmacotherapy in the treatment of oncology.
Katedra I Zakład Farmakologii, Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznań, Polska, Katedra I Zakład Immunologii Klinicznej, Uniwersytet Medyczny Im. Karola Marcinkowskiego, Poznań, Polska, Katedra I Klinika Hematologii I Transplantacji Szpiku, Uniwersytet Medyczny Im. Karola Marcinkowskiego, Poznań, Polska.
Maciej
M
Majcherek
Katedra I Zakład Farmakologii, Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznań, Polska.
Marzena
M
Dworacka
Katedra I Zakład Immunologii Klinicznej, Uniwersytet Medyczny Im. Karola Marcinkowskiego, Poznań, Polska.
Grzegorz
G
Dworacki
D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D010880:Piperidines; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
 Bruton’s kinase inibitors ;  chronic lymphocytic lymphoma; : Ibrutinib